Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Prostate Cancer Prevention (PDQ®): Patient Version.

PDQ Screening and Prevention Editorial Board.

PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-.
2019 May 10.

2.

Potential of hyperbaric oxygen in urological diseases.

Tanaka T, Minami A, Uchida J, Nakatani T.

Int J Urol. 2019 May 13. doi: 10.1111/iju.14015. [Epub ahead of print] Review.

PMID:
31083787
3.

How does 68 Ga-prostate-specific membrane antigen positron emission tomography/computed tomography impact the management of patients with prostate cancer recurrence after surgery?

Bianchi L, Schiavina R, Borghesi M, Ceci F, Angiolini A, Chessa F, Droghetti M, Bertaccini A, Manferrari F, Marcelli E, Cochetti G, Porreca A, Castellucci P, Fanti S, Brunocilla E.

Int J Urol. 2019 May 13. doi: 10.1111/iju.14012. [Epub ahead of print]

PMID:
31083784
4.

PSMA-ligand PET allows a more accurate therapeutic response evaluation of bone metastases in prostate cancer compared to computed tomography.

Fech V, Alberts I, Rominger A, Afshar-Oromieh A.

Nuklearmedizin. 2019 May 13. doi: 10.1055/a-0895-5078. [Epub ahead of print]

PMID:
31083752
5.

Castration-resistant prostate cancer: Androgen receptor inactivation induces telomere DNA damage, and damage response inhibition leads to cell death.

Reddy V, Iskander A, Hwang C, Divine G, Menon M, Barrack ER, Reddy GP, Kim SH.

PLoS One. 2019 May 13;14(5):e0211090. doi: 10.1371/journal.pone.0211090. eCollection 2019.

6.

A Role for NF-κB in Organ Specific Cancer and Cancer Stem Cells.

Kaltschmidt C, Banz-Jansen C, Benhidjeb T, Beshay M, Förster C, Greiner J, Hamelmann E, Jorch N, Mertzlufft F, Pfitzenmaier J, Simon M, Schulte Am Esch J, Vordemvenne T, Wähnert D, Weissinger F, Wilkens L, Kaltschmidt B.

Cancers (Basel). 2019 May 11;11(5). pii: E655. doi: 10.3390/cancers11050655. Review.

7.

Deoxynivalenol Modulates the Viability, ROS Production and Apoptosis in Prostate Cancer Cells.

Habrowska-Górczyńska DE, Kowalska K, Urbanek KA, Domińska K, Sakowicz A, Piastowska-Ciesielska AW.

Toxins (Basel). 2019 May 11;11(5). pii: E265. doi: 10.3390/toxins11050265.

8.

Androgen receptor variant 7 (AR-V7) in sequencing therapeutic agents for castratrion resistant prostate cancer: A critical review.

Sciarra A, Gentilucci A, Silvestri I, Salciccia S, Cattarino S, Scarpa S, Gatto A, Frantellizzi V, Von Heland M, Ricciuti GP, Del Giudice F, Maggi M.

Medicine (Baltimore). 2019 May;98(19):e15608. doi: 10.1097/MD.0000000000015608.

9.

Treating the primary in metastatic prostate cancer: where do we stand?

Nason GJ, Hamilton RJ.

Curr Opin Support Palliat Care. 2019 May 10. doi: 10.1097/SPC.0000000000000432. [Epub ahead of print]

PMID:
31082943
10.

Postoperative Venous Thromboembolism and other Complications after Anatomic Total Shoulder Arthroplasty in Patients With a History of Prostate or Breast Cancer.

Chen DQ, Montgomery SR Jr, Cancienne JM, Werner BC.

J Am Acad Orthop Surg. 2019 May 7. doi: 10.5435/JAAOS-D-18-00777. [Epub ahead of print]

PMID:
31082867
11.

Applying a variable relative biological effectiveness (RBE) might affect the analysis of clinical trials comparing photon and proton therapy for prostate cancer.

Marteinsdottir M, Paganetti H.

Phys Med Biol. 2019 May 13. doi: 10.1088/1361-6560/ab2144. [Epub ahead of print]

PMID:
31082810
12.

Incorporating dosimetric features into the prediction of 3D VMAT dose distributions using deep convolutional neural network.

Ma M, Kovalchuk N, Buyyounouski MK, Xing L, Yang Y.

Phys Med Biol. 2019 May 13. doi: 10.1088/1361-6560/ab2146. [Epub ahead of print]

PMID:
31082805
13.

Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial.

Morris MJ, Loriot Y, Sweeney CJ, Fizazi K, Ryan CJ, Shevrin DH, Antonarakis ES, Pandit-Taskar N, Deandreis D, Jacene HA, Vesselle H, Petrenciuc O, Lu C, Carrasquillo JA, Higano CS.

Eur J Cancer. 2019 May 10;114:107-116. doi: 10.1016/j.ejca.2019.04.007. [Epub ahead of print]

PMID:
31082669
14.

Profiling of differentially expressed genes in cadmium-induced prostate carcinogenesis.

Kolluru V, Tyagi A, Chandrasekaran B, Damodaran C.

Toxicol Appl Pharmacol. 2019 May 11;375:57-63. doi: 10.1016/j.taap.2019.05.008. [Epub ahead of print]

PMID:
31082426
15.

Surgical Management of Patients with Advanced Germ Cell Tumors Following Salvage Chemotherapy: Memorial Sloan Kettering Cancer Center (MSKCC) Experience.

Miller MI, Feifer A, Feldman DR, Carver BS, Bosl GJ, Motzer RJ, Bajorin DF, Sheinfeld J.

Urology. 2019 Feb;124:174-178. doi: 10.1016/j.urology.2018.09.024. Epub 2018 Oct 6.

PMID:
30296502

Supplemental Content

Loading ...
Support Center